Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORTREL 7/7/7 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norelgestromin terminal half-life is approximately 28 hours; ethinyl estradiol terminal half-life is approximately 17 hours. The extended half-life supports once-weekly dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism. Norethindrone: metabolized by reduction and conjugation; primarily via CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal excretion of metabolites (primarily ethinyl estradiol and norelgestromin conjugates) accounts for approximately 50% of elimination; fecal/biliary excretion accounts for the remainder (about 35-40% fecal, 10-15% biliary).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norelgestromin is 99% bound primarily to albumin and sex hormone-binding globulin; ethinyl estradiol is 98% bound primarily to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norelgestromin apparent Vd/F is approximately 2.1 L/kg; ethinyl estradiol apparent Vd/F is approximately 5.5 L/kg, indicating extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Transdermal bioavailability of norelgestromin and ethinyl estradiol is approximately 60-65% relative to oral administration due to avoidance of first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for decreased drug elimination and hormonal alterations.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease or severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class A or B, use with caution; consider alternative contraception due to possible impaired hormone metabolism. No specific dose adjustment guidelines available.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy in postmenarchal pediatric patients have been established. Dose is the same as for adults: one tablet orally once daily following the 28-day regimen.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No studies in geriatric population; use is not appropriate due to lack of need for contraception.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events. Use is contraindicated in women over 35 who smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease. Discontinue if jaundice, visual disturbances, or migraine occurs. Blood pressure should be monitored.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis, thromboembolic disorders, cerebral vascular disease, coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, liver tumor or active liver disease, hypersensitivity to components, and women over 35 who smoke.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure but not considered clinically relevant. Avoid herbal supplements such as St. John's wort, which can reduce contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: No known association with major congenital anomalies based on population data. However, exposure to ethinyl estradiol and norethindrone acetate is not recommended during pregnancy due to theoretical risks from hormonal exposure. Second and third trimesters: Not indicated for use; hormonal contraceptives should be discontinued if pregnancy occurs. No evidence of fetal harm from inadvertent use early in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Combined hormonal contraceptives may reduce milk production and pass into breast milk. The M/P ratio for ethinyl estradiol is approximately 0.3-0.5; for norethindrone, minimal transfer. Use is generally not recommended during breastfeeding, especially in the early postpartum period. Alternative contraception advised.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated during pregnancy. No pharmacokinetic studies in pregnant women; no dose adjustments needed as drug is discontinued. Standard dosing for non-pregnant women: 7 tablets of 0.035 mg ethinyl estradiol/0.5 mg norethindrone, then 7 tablets of 0.035 mg EE/0.75 mg NE, then 7 tablets of 0.035 mg EE/1 mg NE.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
NORTREL 7/7/7 is a triphasic oral contraceptive. The 7/7/7 dosing (7 days of 35 mcg EE/0.5 mg norethindrone, 7 days of 35 mcg EE/0.75 mg norethindrone, 7 days of 35 mcg EE/1 mg norethindrone) mimics natural cycle. Missed dose management: if missed one active pill, take as soon as remembered; if missed two or more, use backup contraception for 7 days and consider emergency contraception. Breakthrough bleeding is common in first 3 cycles. Drug interactions: rifampin, certain anticonvulsants, and some antibiotics may reduce efficacy. Contraindicated in women with migraines with aura, history of DVT/PE, active liver disease, or breast cancer. Monitor blood pressure at baseline and follow-up.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day, following the 7/7/7 sequence.,Missed pill instructions: if you miss one active pill, take it as soon as you remember and continue the pack; if you miss two or more active pills, take the most recent missed pill, discard others, use backup contraception for 7 days, and consider emergency contraception.,Common side effects include nausea, breast tenderness, breakthrough bleeding, and mood changes; these often improve after 3 cycles.,Seek emergency care if you experience leg pain/swelling, chest pain, sudden severe headache, or vision changes, which may signal a blood clot.,Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old.,Tell your doctor about all medications you take, including antibiotics and herbal supplements like St. John's wort.,If you miss a period, take a pregnancy test and contact your doctor.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORTREL 7/7/7 vs AFIRMELLE, answered by our medical review team.
NORTREL 7/7/7 is a Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORTREL 7/7/7 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORTREL 7/7/7 is: One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORTREL 7/7/7 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORTREL 7/7/7 is classified as Category C. First trimester: No known association with major congenital anomalies based on population data. However, exposure to ethinyl estradiol and norethindrone acetate is not recommended . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.